Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 14/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16017549 | 0.86 | DRD2 (0.49) | DRD2CCNT1CDK9HTR1ADRD4 | |
| SCHEMBL16020307 | 0.85 | DRD2 (0.48) | DRD2CCNT1CDK9HTR1ADRD4 | |
| SCHEMBL28210559 | 0.79 | DRD2 (0.52) | DRD2CACNA1HSIGMAR1CD274 | |
| SCHEMBL21214308 | 0.79 | DRD2 (0.55) | DRD2CACNA1HSIGMAR1CD274 | |
| SCHEMBL31301242 | 0.78 | DRD2 (0.63) | DRD2CACNA1HSIGMAR1CD274 | |
| SCHEMBL1620776 | 0.77 | DRD2 (0.55) | DRD2CACNA1HSIGMAR1 | |
| SCHEMBL30945677 | 0.77 | DRD2 (0.65) | DRD2DRD4SIGMAR1 | |
| SCHEMBL2870818 | 0.77 | DRD2 (0.53) | DRD2CACNA1HSIGMAR1CD274 | |
| SCHEMBL24172673 | 0.75 | DRD2 (0.56) | DRD2CACNA1HSIGMAR1CD274 | |
| SCHEMBL4024516 | 0.75 | DRD2 (0.56) | DRD2CACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2710018-B1 | MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | FUNDACION CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) | 2021-12-29 | — | — | EP | disclosed |
| US-9808466-B2 | Macrocyclic compounds as protein kinase inhibitors | FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III | 2017-11-07 | — | — | US | disclosed |
| US-20160296528-A1 | MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2016-10-13 | — | — | US | disclosed |
| WO-2012156756-A2 | NEW COMPOUNDS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160296528-A1 | MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | PIM1, PIM3, PIM2 | DRD2 3934/4885CCNT1 509/4885CDK9 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.